Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
Attovia Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
No price to book ratio figures for Attovia Therapeutics
Attovia Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?